{"nctId":"NCT01470989","briefTitle":"Î²-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)","startDateStruct":{"date":"2011-11"},"conditions":["Acute Gouty Arthritis Flares"],"count":136,"armGroups":[{"label":"canakinumab","type":"EXPERIMENTAL","interventionNames":["Drug: ACZ885","Drug: Triamcinolone acetonide 40 mg"]}],"interventions":[{"name":"ACZ885","otherNames":["Canakinumab"]},{"name":"Triamcinolone acetonide 40 mg","otherNames":["Triamcinolone acetonide"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients who have completed the second extension studies CACZ885H2356E2 or CACZ885H2357E2\n* Patients treated with canakinumab in the core studies or subsequent extensions\n\nExclusion Criteria:\n\n\\- Pregnant or nursing (lactating) women","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Incidence Rate (IR) of Adverse Events, Serious Adverse Events and Death Per 100 Patient-years in Participants","description":"Adverse events (AEs) were defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome or disease which either occurs during study, having been absent at baseline,or, if present at baseline, appears to worsen. Serious adverse events (SAEs) were defined as any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgement of investigators represent significant hazards.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"873","spread":null},{"groupId":"OG001","value":"451","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59","spread":null},{"groupId":"OG001","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of New Flares Per Participant","description":"Flare rate was calculated as the number of new flares over the period of observation in years. New flares occurred before first study medication dose in extension 3 study were considered.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.109","spread":"1.608"},{"groupId":"OG001","value":"2.459","spread":"3.701"}]}]}]},{"type":"SECONDARY","title":"Patient's Assessment of Gout Pain Intensity in the Most Affected Joint","description":"Participant scored their current pain intensity in the most affected joint of the gout flare on a 5-point Likert Scale (none or mild).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"102","spread":null},{"groupId":"OG001","value":"72","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"104","spread":null},{"groupId":"OG001","value":"69","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":35,"n":225},"commonTop":["Hypertension","Arthralgia","Upper respiratory tract infection","Headache","Back pain"]}}}